9 Result(s)
within
Medicine/Public Health, general
Christopher L Corless
-
Article
c-CBL is not required for leukemia induction by Bcr-Abl in mice
Bcr-Abl tyrosine kinase activity is essential for the pathogenesis of chronic myeloid leukemia (CML). A number of Bcr-Abl substrates have been identified, but it is not clear which of these substrates are require...
-
Article
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles
Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates wi...
-
Article
Does tumor mutational status correlate with clinical response to imatinib?
-
Article
Open AccessIntegrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)
About 10-15% of adult gastrointestinal stromal tumors (GIST) and the vast majority of pediatric GIST do not harbour KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations (J Clin Oncol 22:3813–38...
-
Article
Open AccessFGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors
About 10–15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1). The identification of additional mutated gene...
-
Article
Open AccessImplementing a comprehensive translational oncology platform: from molecular testing to actionability
In order to establish the workflows required to implement a real-time process involving multi-omic analysis of patient samples to support precision-guided therapeutic intervention, a tissue acquisition and ana...
-
Article
Open AccessLoss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma
Plexiform fibromyxoma (PF) is a rare gastric tumor often confused with gastrointestinal stromal tumor. These so-called “benign” tumors often present with upper GI bleeding and gastric outlet obstruction. It wa...
-
Article
Open AccessCharacterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges in accurately characterizing and treating the disease. Current diagnostic approaches offer limited ability to assess he...
-
Article
Open AccessMultiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies
In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as...
